ArticleFrontiers in medicine2025
Solute carrier family 1 member 1 in renal interstitial fibrosis: evaluating its influence on glutamate uptake and extracellular ion levels.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Goal: This research sought to examine the role of solute carrier family 1 member 1 (SLC1A1) in renal interstitial fibrosis (RIF), exploring its relationship with fibrosis extent and its influence on amino acids absorption and ion levels. Approach: Renal tubulointerstitial damage was assessed using tissue microarray analysis combined with HE staining. Immunohistochemistry was used to identify SLC1A1 expression in fibrotic tissues, and its relationship with renal tubulointerstitial damage was examined. Additionally, an Finding: The expression of SLC1A1 decreases in cases of renal interstitial fibrosis, with a more pronounced reduction as fibrosis worsens. Following 48 h of exposure to TGF-β1 (15 ng/mL), these alterations became even more apparent. At this 48 h mark, the glutamate uptake in the experimental group was significantly lower compared to the control group, while the levels of extracellular Na Conclusion: The downregulation of SLC1A1 during renal interstitial fibrosis is inversely related to the severity of fibrosis and impacts both glutamate uptake and the balance of extracellular ions, indicating its potential as a therapeutic target for enhancing kidney function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.